A Quick Primer On Roche's Immuno-Oncology Assets
Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.
You may also be interested in...
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
Two studies published in Nature July 5 showed that personalized cancer vaccines from BioNTech and Neon Therapeutics delivered potent immune responses in patients with melanoma. Both companies are moving forward with new studies.
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.